NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in fireside chats at the following investor conferences:
Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023, at 1:50 pm ET
Evercore ISI 6th Annual HealthCONx Conference on Tuesday, November 28, 2023, at 5:05 pm ET
Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30, 2023, at 11:30 am ET
The fireside chats will be webcast live and can be accessed here. An archived webcast will be available for a limited time on Immunovant’s website.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit www.immunovant.com.
Contact:
Chau Cheng, PhD, MBA
Vice President, Investor Relations
Immunovant, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Jaye Bea Smalley
Head, Patient Advocacy
Immunovant, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$29.26 |
| Daily Change: | 0.71 2.49 |
| Daily Volume: | 652,390 |
| Market Cap: | US$4.280B |
September 09, 2024 September 05, 2024 August 06, 2024 March 12, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
